Neogen vs Trinity Biotech: revenue, profit, margins and growth compared
Neogen brought in $870.4M of revenue in fiscal 2026, Trinity Biotech $61.6M in fiscal 2024. Revenue changed by -2.7% at Neogen and +8.3% at Trinity Biotech on the year before, so Trinity Biotech grew faster. Neogen kept -0.9% of its revenue as net profit, Trinity Biotech -51.6%. Free cash flow was $31.9M at Neogen and -$4.6M at Trinity Biotech.
Fiscal years as each company reports them; the two may end in different months.
Questions about Neogen and Trinity Biotech
Which is bigger by revenue, Neogen or Trinity Biotech?
Neogen is bigger by revenue: $870.4M in fiscal 2026, against $61.6M for Trinity Biotech in fiscal 2024.
Which keeps more of its revenue as profit, Neogen or Trinity Biotech?
Neogen had a net margin of -0.9% in fiscal 2026; Trinity Biotech had -51.6% in fiscal 2024.
Which grew revenue faster, Neogen or Trinity Biotech?
In their latest fiscal years revenue changed by -2.7% at Neogen and +8.3% at Trinity Biotech.
Where do these numbers come from?
From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.